“Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytrens disease,” said a researcher, Jagdeep Nanchahal. Two weeks prior to surgery they received a single injection of varying doses of the anti-TNF drug, or placebo. “We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early-stage Dupuytrens disease,” said another researcher, Sir Marc Feldmann.”The Kennedy Institute has a long history of successfully translating laboratory findings to the clinic” said another lead researcher, Fiona Powrie. The results so far are very promising. “This type of work requires close collaboration between laboratory scientists, clinical trialists and clinician scientists over many years,” she added.Dupuytrens disease is a common condition that causes the fingers to curl irreversibly into the palm. They also found the drug to be safe and well tolerated.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post-injection, suggesting this drug could be used to stop the growth of disease-causing myofibroblast cells. The team found that adalimumab (at a dose of 40mg formulated in 0.Washington: Patients with incurable hand disabling condition, called Dupuytrens disease, have a ray of hope. And then theres the lengthy recovery ahead, a less than ideal situation to find yourself in,” he added.
Researchers have found that an injection of the anti-Tumour Necrosis Factor (TNF) drug adalimumab into Dupuytrens disease nodules results in reduction of the cell characteristics responsible for the progression of Dupuytrens disease. “This brings Wholesale Heavy Duty Hand Riveter for sale new hope to people who suffer from this disabling condition, who currently have to wait for their situation to deteriorate, watching their hand lose function until it is bad enough for surgery..The anti-TNF drug adalimumab (Humira) is currently licensed in the EU for the treatment of a number of conditions including rheumatoid arthritis, Crohns disease and ulcerative colitis and overall has an excellent safety profile.This randomised trial (phase 2a) recruited 28 patients with Dupuytrens disease who were scheduled to undergo surgery to remove diseased tissue in their hand.The tissue removed during surgery, which is usually discarded, was then analysed in the laboratory. Marc and his team identified TNF as a therapeutic target in patients with rheumatoid arthritis.Based on the research, that TNF drives the development of myofibroblasts, the cell type that causes Dupuytrens disease, the research team explored the effects of an anti-TNF drug injected directly into the Dupuytrens nodule tissue.The study appears in EBioMedicine journal.
Tangwen Tools Co., Ltd